anti-PD-L1
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
11
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
14
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
7
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
9
Irradiation and anti–PD L1 treatment synergistically promote antitumor immunity in mice
10
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
12
Enhanced killing of chordoma cells by antibody-dependent cell- mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
14
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
12
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
14
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
16
Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma
13
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
10
Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors
8
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
6
Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
12
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
16
Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade
15
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
10
Expression of PD L1 in triple negative breast cancer based on different immunohistochemical antibodies
12
Targeting PD-1/PD-L1 in lung cancer: current perspectives
16